Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.8935.9629
Address
Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113
Description
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.8 - 6.0
Trade Value (12mth)
AU$12,836.00
1 week
-2.34%
1 month
27.55%
YTD
-55.36%
1 year
-55.36%
All time high
81.76
EPS 3 yr Growth
-44.40%
EBITDA Margin
%
Operating Cashflow
-$11m
Free Cash Flow Return
-147.50%
ROIC
-162.30%
Interest Coverage
-3,293.30
Quick Ratio
3.30
Shares on Issue (Fully Dilluted)
10m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
09 July 25 |
Update - Proposed issue of securities - OSL
×
Update - Proposed issue of securities - OSL |
09 July 25 |
Update - Proposed issue of securities - OSL
×
Update - Proposed issue of securities - OSL |
09 July 25 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
08 July 25 |
Results of Meeting
×
Results of Meeting |
07 July 25 |
OSL completes $2 million Share Purchase Plan
×
OSL completes $2 million Share Purchase Plan |
04 July 25 |
Completion of Recruitment in PANCOSIL Study
×
Completion of Recruitment in PANCOSIL Study |
26 June 25 |
Becoming a substantial shareholder from AEF
×
Becoming a substantial shareholder from AEF |
25 June 25 |
Change of Directors Interest Notice Lel Smits
×
Change of Directors Interest Notice Lel Smits |
19 June 25 |
Notification regarding unquoted securities - OSL
×
Notification regarding unquoted securities - OSL |
19 June 25 |
Notification of cessation of securities - OSL
×
Notification of cessation of securities - OSL |
18 June 25 |
Change in substantial holding from SOL
×
Change in substantial holding from SOL |
17 June 25 |
Change in substantial holding from PCG
×
Change in substantial holding from PCG |
06 June 25 |
Capital Consolidation Complete
×
Capital Consolidation Complete |
06 June 25 |
Update - Consolidation/Split - OSL
×
Update - Consolidation/Split - OSL |
06 June 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
04 June 25 |
Security Purchase Plan (SPP) Now Open
×
Security Purchase Plan (SPP) Now Open |
03 June 25 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
03 June 25 |
Notice under section 708A
×
Notice under section 708A |
29 May 25 |
Results of Meeting
×
Results of Meeting |
29 May 25 |
Update - Consolidation/Split - OSL
×
Update - Consolidation/Split - OSL |
26 May 25 |
OSL announces $8.7m capital raise to drive commercialisation
×
OSL announces $8.7m capital raise to drive commercialisation |
26 May 25 |
Prospectus
×
Prospectus |
26 May 25 |
Investor Presentation
×
Investor Presentation |
26 May 25 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
26 May 25 |
Proposed issue of securities - OSL
×
Proposed issue of securities - OSL |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.